AstraZeneca Pharma India Limited

NSEI:ASTRAZEN 株式レポート

時価総額:₹158.4b

AstraZeneca Pharma India マネジメント

マネジメント 基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Sanjeev Panchal

最高経営責任者

₹38.7m

報酬総額

CEO給与比率83.4%
CEO在任期間1.8yrs
CEOの所有権n/a
経営陣の平均在職期間1.3yrs
取締役会の平均在任期間less than a year

経営陣の近況

Recent updates

AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Earnings Haven't Escaped The Attention Of Investors

Sep 18
AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Earnings Haven't Escaped The Attention Of Investors

We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability

Jun 03
We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability

Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S

May 22
Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S

We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease

Apr 04
We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease

Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

Nov 10
Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00

Jul 06
AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00

Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

Jun 16
Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)

Aug 02
Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)

Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock

Feb 25
Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock

Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

Feb 04
Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

Jan 18
Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years

Dec 31
Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years

We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability

Dec 13
We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability

Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching

Nov 25
Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching

Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay

Nov 07
Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay

What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

Oct 20
What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Sep 24
AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today

Aug 28
If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today

What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?

Aug 02
What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?

CEO報酬分析

AstraZeneca Pharma India の収益と比較して、Sanjeev Panchal の報酬はどのように変化したか?
日付総報酬給与会社業績
Sep 30 2024n/an/a

₹819m

Jun 30 2024n/an/a

₹959m

Mar 31 2024₹39m₹32m

₹2b

Dec 31 2023n/an/a

₹1b

Sep 30 2023n/an/a

₹2b

Jun 30 2023n/an/a

₹1b

Mar 31 2023₹21m₹5m

₹993m

報酬と市場: Sanjeevの 総報酬 ($USD 458.59K ) は、 Indian市場 ($USD 481.61K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Sanjeevの報酬は 20% 以上増加しましたが、会社の収益は過去 1 年間で 20% 以上減少しました。


CEO(最高経営責任者

Sanjeev Panchal (47 yo)

1.8yrs

在職期間

₹38,725,314

報酬

Dr. Sanjeev Kumar Panchal serves as Country President of AstraZeneca Pharma India Limited since January 01, 2023 and serves as its Managing Director since January 01, 2023. He serves as Director of AstraZe...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Sanjeev Panchal
MD, Country President & Director1.8yrs₹38.73mデータなし
Bhavana Agrawal
Whole-Time Director & CFO1.1yrs₹30.59mデータなし
Pratap Bhuvanagiri
Legal Counsel7.8yrs₹3.73mデータなし
Manasa R.
Company Secretary & Compliance Officer2.3yrsデータなしデータなし
Smita Saha
Vice President of Human Resourcesno data₹12.28mデータなし
Ayush Agarwal
Interim Business Unit Head of Oncology & Director of Commercial Excellence1.3yrsデータなしデータなし
Praveen Akkinepally
Head of Oncology Business Unitless than a yearデータなしデータなし
Vinay Sharma
Business Unit Head - Rare Disease unitless than a yearデータなしデータなし
Pankaj Jain
Legal Headno dataデータなしデータなし

1.3yrs

平均在職期間

経験豊富な経営陣: ASTRAZENの経営陣は 経験豊富 とはみなされません ( 1.3年の平均在職年数)。これは新しいチームを示唆しています。


取締役

名称ポジション在職期間報酬所有権
Sanjeev Panchal
MD, Country President & Director1.8yrs₹38.73mデータなし
Bhavana Agrawal
Whole-Time Director & CFOless than a year₹30.59mデータなし
Revathy Ashok
Independent Non-Executive Director7.9yrs₹1.20mデータなし
Monica Widhani
Additional Independent Directorless than a yearデータなしデータなし
Hooi Chuah
Additional Non-Executive Directorless than a yearデータなしデータなし
Nirula Shilpa Divekar
Independent Non-Executive Chairperson of the Board2.9yrs₹1.30mデータなし
Sylvia Lorena Ramon
Non-Executive Directorless than a yearデータなしデータなし
Jesus Javier Diaz Esteso
Additional Non-Executive Directorno dataデータなしデータなし

0.9yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: ASTRAZENの 取締役会経験豊富 ではない ( 0.9年の平均在任期間) ため、新しい取締役会が必要であると考えられます。